Kailera Therapeutics Completes $625 Million IPO, Largest in Biotech History

Kailera Therapeutics has completed a $625 million IPO, the largest in biotech history, with shares priced at $16 each. The company plans to use the funds to advance its obesity treatments, including ribupatide, and expand its pipeline. The IPO follows a $400 million Series A in October 2024.

By Annabel Kartal Allen Fri, April 17, 2026 at 6:30 PM GMT+3 3 min read · Yahoo Finance · April 17, 2026, 15:30 UTC

Kailera Therapeutics Completes $625 Million IPO, Largest in Biotech History

Tickers: $LLY $MRNA $NVO

Topics: Biotech Funding IPO Kailera Therapeutics Market Expansion Obesity Treatment

Read the full article at Yahoo Finance

More World news

Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC